US 12,029,761 B2
Guidance and Navigation Control proteins and method of making and using thereof
Yi Zhu, Sichuan (CN); Ole Olsen, Everett, WA (US); Dong Xia, Redmond, WA (US); David Jellyman, Duvall, WA (US); Katrina Bykova, Seattle, WA (US); Anne-Marie Rousseau, Seattle, WA (US); Bill Brady, Bothell, WA (US); Blair Renshaw, Renton, WA (US); Brian Kovacevich, Snohomish, WA (US); Yu Liang, Redmond, WA (US); Camilla Wang, Sammamish, WA (US); Zeren Gao, Redmond, WA (US); and Hui Huang, Redmond, WA (US)
Assigned to SYSTIMMUNE, INC., Redmond, WA (US)
Appl. No. 17/040,513
Filed by SYSTIMMUNE, INC., Redmond, WA (US); and SICHUAN BAILI PHARMACEUTICAL CO. LTD., Sichuan (CN)
PCT Filed Mar. 26, 2019, PCT No. PCT/US2019/024105
§ 371(c)(1), (2) Date Sep. 22, 2020,
PCT Pub. No. WO2019/191120, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/648,880, filed on Mar. 27, 2018.
Claims priority of provisional application 62/648,888, filed on Mar. 27, 2018.
Prior Publication US 2021/0024630 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/70503 (2013.01); C07K 14/7051 (2013.01); C07K 14/70532 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C12N 5/0638 (2013.01); C12N 5/0693 (2013.01); G01N 33/57488 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. A guidance and navigation control (GNC) protein, comprising,
a binding domain for a T cell activating receptor, wherein the T cell activating receptor comprises CD3,
a binding domain for a tumor associated antigen, wherein the tumor associated antigen comprises EGFRvIII, CD19, or ROR1,
a binding domain for an immune checkpoint receptor, wherein the immune checkpoint receptor comprises PD-L1, and
a binding domain for a T cell co-stimulating receptor, wherein the T cell co-stimulating receptor comprises 4-1 BB,
wherein the binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor.